NIOX Directors Exercise Options as Share Capital Rises

Circassia Pharmaceuticals ( (GB:NIOX) ) just unveiled an announcement.

NIOX Group plc has issued 1,466,320 new ordinary shares after three board directors exercised performance share options, with the resulting awards ranking pari passu with existing stock. Two of the directors, CEO Jonathan Emms and CFO Sarah Duncan, sold 489,885 shares at 56.4 pence to cover tax and related costs, modestly increasing their net holdings.

Additional employee option exercises over 872,681 shares have lifted NIOX’s total issued share capital to 420,413,454 ordinary shares, each carrying one voting right. The updated share count slightly dilutes existing shareholders but clarifies the new denominator for regulatory disclosure thresholds under the FCA’s transparency rules.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £86.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Spark’s Take on NIOX Stock

According to Spark, TipRanks’ AI Analyst, NIOX is a Neutral.

The score is primarily supported by strong financial quality (growth, profitability, low debt, and solid cash generation). It is held back by bearish technical signals (price below major moving averages and negative MACD) and a high P/E that is only partly offset by the dividend yield.

To see Spark’s full report on NIOX stock, click here.

More about Circassia Pharmaceuticals

NIOX Group plc is a UK-listed medical diagnostics company focused on respiratory health. The group develops and markets devices and tests for measuring airway inflammation, with its ordinary shares traded on London’s AIM market under the ticker NIOX.

Average Trading Volume: 807,102

Technical Sentiment Signal: Sell

Current Market Cap: £235.8M

For a thorough assessment of NIOX stock, go to TipRanks’ Stock Analysis page.